Drugs / AMG 340
last change Jun 2024 re-read 3 minutes ago

AMG 340

Developed for
castration-resistant prostate carcinoma
Investigated by
Amgen

Trials 1

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04740034 Apr 2021 → Jun 2024 castration-resistant prostate carcinoma Amgen Terminated No outcome recorded Stop: Business

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AMG 340 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04740034 ↗